# Source-first research: 1,500-workflow completion

## Milestone

- Branch: `source-first-guideline-expansion-1500-v2`
- Final-range starting HEAD: `2d36d8671bcb1f4e90c95cab52b5ca4c40944df0`
- Ending programme-state HEAD before this milestone report: `cae8a445d87724ea6cf31fc91e8f007077c66123`
- Queue status: `SOURCE_FIRST_RESEARCH_COMPLETE`
- Terminal workflows: 1,500
- Research-interrupted workflows: 0
- Workflows remaining `not_started`: 0
- Next workflow: none

All 1,500 workflows now have an approved terminal research status. The queue and restart state contain a null `next_workflow_id`, no research-queue resume command, and no invented workflow 1501. The source-first research queue is closed; no next programme phase was started.

## Final research reconciliation

| Research status | Count |
|---|---:|
| Exact workflow source verified | 0 |
| Partial exact source verified | 1,099 |
| No authoritative source found | 401 |
| Conflicting authoritative sources | 0 |
| Source access failed | 0 |
| Other approved terminal statuses | 0 |
| **Terminal total** | **1,500** |
| **Research interrupted** | **0** |

The status counts reconcile exactly to 1,500. Queue completion does not change the clinical meaning of these outcomes: partial and no-authoritative-source workflows remain clinical blockers, and no item-level support was inferred from terminal research status.

## UAE applicability

- Structured findings: 1,426
- Affected workflows: 1,401
- Partial-applicability findings: 1,099
- Missing-explicit-UAE-evidence findings: 327
- Other findings: 0

International guidance remains non-UAE-specific unless direct UAE evidence is recorded. The remaining UAE audit is a programme blocker, not a queue-completion defect.

## Sources, recency, and replay

- Registered sources: 235
- New sources in the final range: 0
- Source-recency status: PASS
- Recheck due: 23
- Recency outcomes: 24 explicit-stronger-date current, 3 approved-unknown current by verification, 65 weaker-metadata current, 120 access-verification current, 23 recheck due, and zero unavailable, superseded, incomplete, or expired
- Replay modules: 151
- Initial-source modules: 1
- Numbered batch modules: 150
- Source operations: 251
- Replayed sources: 235
- Replay parity differences: 0
- Metadata fingerprint: `7c54674e1c2e367d16db03d482f9bcda9bafcfbdda4f2547392760d141bb9497`
- Replay-manifest fingerprint: `53109420feff822fa7d82266c7a6325135b5092a7b3c2662f5055e8d995edbf0`

Persisted provenance, source recency, active metadata, independent replay, and stored fingerprints remain deterministic and equal. Source registries were not changed by the final workflow range.

## Final validation matrix

Twenty of the 23 required commands passed. Only the three authorized clinical programme blockers remain.

| Validation group | Result |
|---|---|
| Signed and canonical reconciliation | PASS |
| Candidate separation and canonical write authority | PASS |
| Data, evidence, provenance, research claims, safety, workflows, output, and exclusions | PASS |
| Evidence hashes and clinical-data reproducibility | PASS |
| Research queue tests | PASS (16/16, including terminal completion) |
| Lint | PASS with pre-existing warnings |
| Build | PASS |
| Exact-source coverage | AUTHORIZED BLOCKER: 1,500 workflows lack complete exact-source coverage |
| UAE applicability | AUTHORIZED BLOCKER: 1,426 findings across 1,401 workflows |
| Unsupported legacy content | AUTHORIZED BLOCKER: 83,303 items |

## Remaining programme boundaries

- Canonical mappings: 0
- Candidate proposals: 0
- Source-derived legacy items: 0
- Unsupported legacy items: 83,303
- Active exclusions: 12
- Proposed exclusions: 0
- Public data changed: no
- Source registries changed: no
- Canonical mapping state changed: no
- Signed approval state changed: no

The protected public-data, exclusion, canonical, approval, and signed-state boundaries match the required starting state. No push, deployment, merge, rebase, signing, or approval occurred.

## Recommended next programme phase

The next phase should be separately authorized qualified-clinician review and item-level evidence mapping, prioritized by clinical risk and UAE applicability gaps, with candidate proposals kept separate from signed canonical activation. It should retain the existing provenance, recency, replay, fingerprint, exclusion, and signed-approval gates. This report records that recommendation only; the next phase has not begun.

## Completion commits before this report

- `8ab6635` — `research(source-first): process workflows 1476 to 1500`
- `78b2f1b` — `chore(source-first): complete source-first research queue`
- `cae8a44` — `docs(source-first): record final workflow batch`
